Acadia

They will provide more information on the 2014 GMC Acadia online www.

On a business level, ACADIA also noted that it has continued to make considerable progress in its lead clinical programs.

Certain matters in this press release may constitute forward-looking statements within the meaning of federal securities law and as such may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performances or achievements of Acadia to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements.

This release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the purchase of securities of ACADIA and the use of proceeds.

PSI"), has joined Nashville-based Acadia as CEO along with other former PSI senior executive team members.

We are excited that Joey Jacobs and his senior management team have joined Acadia to lead the next chapter of its growth and are fortunate to have the opportunity to partner with a team of this caliber," said Chuck Edwards, Principal at WCP.

Aasen, Vice President and Chief Executive Officer of ACADIA Pharmaceuticals Inc.

ACADIA has agreed to file a registration statement with the SEC covering the resale of the shares of common stock, including the shares of common stock issuable upon exercise of the warrants, sold in the private placement.

In order to focus its resources on this advanced program, ACADIA will not continue with planned clinical trials for pimavanserin in Alzheimer's disease psychosis or schizophrenia at this time.

ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.

ACADIA is developing a portfolio consisting of four product candidates including pimavanserin, which is being developed for three separate neurological and psychiatric indications in collaboration with Biovail.

Aasen, Vice President and Chief Financial Officer of ACADIA Pharmaceuticals, +1-858-558-2871, ir@acadia-pharm.

ACADIA continues to expect its existing cash resources and anticipated payments from its collaborations will be sufficient to fund its operations through the end of 2011.